חוב לטווח קצר של החברה: anbio.com (NNNN)

Anbio Biotechnology management is effectively optimizing logistics and quality control. Partnerships with universities and distributors are helping to implement new tests in new markets. Total short-term debt reflects the dynamics of current liabilities, where 0.00 represents the current metric. The business is currently focusing on aggressive capture of the B2B segment through affordable portable rapid diagnostic systems.

The expansion of Anbio Biotechnology (NNNN) within the portable diagnostics segment requires significant working capital to scale rapid testing. An analysis of short-term financial liabilities allows for the tracking of obligations under one year, revealing hidden intra-period spikes in borrowing. A decrease in this metric confirms high liquidity and business resilience, which directly reduces default risk and optimizes the company's overall cost of capital.